ArticleTargeted oncology2025

Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy.

Doran Ksienski et al.PubMed ↗Publisher ↗

No numbers read from the abstract.